Statin-Associated Autoimmune Myopathy
Top Cited Papers
- 18 February 2016
- journal article
- review article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 374 (7), 664-669
- https://doi.org/10.1056/nejmra1515161
Abstract
Statins are widely used and lower the risk of death from cardiovascular causes. In a fraction of patients, an autoimmune myopathy may develop, characterized by the development of autoantibodies to the target enzyme, HMG-CoA reductase.Keywords
This publication has 36 references indexed in Scilit:
- Acquired necrotizing myopathiesCurrent Opinion in Neurology, 2013
- 3‐hydroxy 3‐methylglutaryl coenzyme a reductase inhibition impairs muscle regenerationJournal of Cellular Biochemistry, 2012
- Rarity of anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase antibodies in statin users, including those with self-limited musculoskeletal side effectsArthritis Care & Research, 2011
- Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statin-associated autoimmune myopathyArthritis & Rheumatism, 2010
- A novel autoantibody recognizing 200‐kd and 100‐kd proteins is associated with an immune‐mediated necrotizing myopathyArthritis & Rheumatism, 2010
- Regulatory interactions between muscle and the immune system during muscle regenerationAmerican Journal of Physiology-Regulatory, Integrative and Comparative Physiology, 2010
- SLCO1B1 variants and statin-induced myopathy - A genomewide studyNew England Journal of Medicine, 2008
- Distribution of creatine kinase in the general population: Implications for statin therapyAmerican Heart Journal, 2007
- Statin Safety: A Systematic ReviewThe American Journal of Cardiology, 2006
- Regulation of the mevalonate pathwayNature, 1990